Long Term Follow-up for Subjects Who Previously Participated in the NTXMCO-002 RESTORE Study.
In: Gene Therapy Weekly, 2023-12-25, S. 1043-1043
serialPeriodical
Zugriff:
This document provides information about a long-term observational study for retinitis patients who previously received a gene therapy product called MCO-010. The study aims to monitor the safety and long-term effects of the treatment. The study is enrolling participants and is expected to be completed by September 2027. The eligibility criteria include being previously enrolled in a related study, able to comprehend and give informed consent, and willing to participate for the full 3-year duration. The study is being conducted by Nanoscope Therapeutics Inc. and will share its results when completed. [Extracted from the article]
Copyright of Gene Therapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Long Term Follow-up for Subjects Who Previously Participated in the NTXMCO-002 RESTORE Study.
|
---|---|
Zeitschrift: | Gene Therapy Weekly, 2023-12-25, S. 1043-1043 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1078-2842 (print) |
Sonstiges: |
|